PVI
PCRX icon

Pura Vida Investments’s Pacira BioSciences PCRX Stock Holding History

Pura Vida Investments’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-42,500
Closed -$1.94M – 84
2017
Q1 		$1.94M Buy
+42,500
New +$1.84M 0.57% 55

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Pura Vida Investments's PCRX Position: Q2 2017 in Review

Pura Vida Investments sold out of Pacira BioSciences (PCRX) in Q2 2017, closing a stake of 42,500 shares — an estimated $1.94M sold.

Pura Vida Investments first reported a position in PCRX in Q1 2017 and held it in 1 quarter. The position peaked at $1.94M in Q1 2017. 196 funds tracked by Wall St. Rank hold PCRX as of Q2 2017.

  • Pura Vida Investments reported no remaining Pacira BioSciences position as of Q2 2017 after selling out during the quarter.
  • Pura Vida Investments sold 42,500 Pacira BioSciences shares in Q2 2017, an estimated $1.94M.
  • Pura Vida Investments first reported a position in Pacira BioSciences in Q1 2017 and held it in 1 quarter.
  • Pura Vida Investments's Pacira BioSciences position peaked at $1.94M in Q1 2017.
  • 196 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2017.

Based on Pura Vida Investments's 13F filing for Q2 2017, filed 14 Aug 2017.